These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 25672677)

  • 21. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis.
    Evoli A; Tonali PA; Padua L; Monaco ML; Scuderi F; Batocchi AP; Marino M; Bartoccioni E
    Brain; 2003 Oct; 126(Pt 10):2304-11. PubMed ID: 12821509
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Transient neonatal myasthenia gravis in a baby born to a mother with new-onset anti-MuSK-mediated myasthenia gravis.
    O'carroll P; Bertorini TE; Jacob G; Mitchell CW; Graff J
    J Clin Neuromuscul Dis; 2009 Dec; 11(2):69-71. PubMed ID: 19955986
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [History of myasthenia gravis].
    Nakata T
    Nihon Rinsho; 1975 May; 33(5):1961-71. PubMed ID: 1097765
    [No Abstract]   [Full Text] [Related]  

  • 24. Rituximab in severe seronegative juvenile myasthenia gravis: review of the literature.
    Koul R; Al Futaisi A; Abdwani R
    Pediatr Neurol; 2012 Sep; 47(3):209-12. PubMed ID: 22883288
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis.
    Zisimopoulou P; Evangelakou P; Tzartos J; Lazaridis K; Zouvelou V; Mantegazza R; Antozzi C; Andreetta F; Evoli A; Deymeer F; Saruhan-Direskeneli G; Durmus H; Brenner T; Vaknin A; Berrih-Aknin S; Frenkian Cuvelier M; Stojkovic T; DeBaets M; Losen M; Martinez-Martinez P; Kleopa KA; Zamba-Papanicolaou E; Kyriakides T; Kostera-Pruszczyk A; Szczudlik P; Szyluk B; Lavrnic D; Basta I; Peric S; Tallaksen C; Maniaol A; Tzartos SJ
    J Autoimmun; 2014 Aug; 52():139-45. PubMed ID: 24373505
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MRI and clinical studies of facial and bulbar muscle involvement in MuSK antibody-associated myasthenia gravis.
    Farrugia ME; Robson MD; Clover L; Anslow P; Newsom-Davis J; Kennett R; Hilton-Jones D; Matthews PM; Vincent A
    Brain; 2006 Jun; 129(Pt 6):1481-92. PubMed ID: 16672291
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Early aggressive treatment strategy against myasthenia gravis.
    Nagane Y; Suzuki S; Suzuki N; Utsugisawa K
    Eur Neurol; 2011; 65(1):16-22. PubMed ID: 21116111
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Myasthenia and the neuromuscular junction.
    Gilhus NE
    Curr Opin Neurol; 2012 Oct; 25(5):523-9. PubMed ID: 22892950
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The predictive value of the presence of different antibodies and thymus pathology to the clinical outcome in patients with generalized myasthenia gravis.
    Nikolic A; Djukic P; Basta I; Hajdukovic Lj; Stojanovic VR; Stevic Z; Nikolic D; Bozic V; Lavrnic S; Lavrnic D
    Clin Neurol Neurosurg; 2013 Apr; 115(4):432-7. PubMed ID: 22770539
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intravenous immune globulin in myasthenia gravis.
    Gajdos P
    Clin Exp Immunol; 1994 Jul; 97 Suppl 1(Suppl 1):49-51. PubMed ID: 8033435
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Antibodies in myasthenia gravis].
    Eymard B
    Rev Neurol (Paris); 2009 Feb; 165(2):137-43. PubMed ID: 19162288
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Therapeutic strategy in myasthenia gravis].
    Tranchant C
    Rev Neurol (Paris); 2009 Feb; 165(2):149-54. PubMed ID: 19233080
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chapter 33: the history of movement disorders.
    Lanska DJ
    Handb Clin Neurol; 2010; 95():501-46. PubMed ID: 19892136
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Myasthenia gravis.
    Kothari MJ
    J Am Osteopath Assoc; 2004 Sep; 104(9):377-84. PubMed ID: 15452103
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of refractory myasthenia: "rebooting" with high-dose cyclophosphamide.
    Drachman DB; Jones RJ; Brodsky RA
    Ann Neurol; 2003 Jan; 53(1):29-34. PubMed ID: 12509845
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Myasthenia gravis with anti-acetylcholine receptor antibody or anti-muscle specific kinase antibody].
    Konishi T
    Brain Nerve; 2011 Jul; 63(7):695-704. PubMed ID: 21747139
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development of a specific immunoadsorbent containing immobilized synthetic peptide of acetylcholine receptor for treatment of myasthenia gravis. 1993.
    Nakaji S; Oka K; Tanihara M; Takakura K; Takamori M
    Ther Apher; 2000 Apr; 4(2):124-6. PubMed ID: 10805430
    [No Abstract]   [Full Text] [Related]  

  • 38. Scientific overview of myasthenia gravis and an assessment of the role of plasmapheresis.
    Tindall RS
    Prog Clin Biol Res; 1982; 106():113-42. PubMed ID: 6757936
    [No Abstract]   [Full Text] [Related]  

  • 39. [Myasthenia gravis].
    Tanaka K
    Nihon Rinsho; 2004 May; 62 Suppl 5():580-5. PubMed ID: 15197988
    [No Abstract]   [Full Text] [Related]  

  • 40. Myasthenia gravis--the first 100 years in perspective.
    Harvey AM
    Trans Am Clin Climatol Assoc; 1971; 82():149-69. PubMed ID: 4934016
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.